Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
GUTS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fractyl Health, Inc. Common StockNASDAQ: GUTS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $9.22M, compared with -$23.74M a year earlier. Trailing-twelve-month net income was -$108M. Over 3 fiscal years it compounded at +44.8% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$53.47M (-62.1%) for the fiscal year ending Dec 2026, a slowdown from the +105.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.22M+121.1% QoQ
- Last fiscal yearDec 2025
- -$140.95M+105.2% YoY
- LTMMar 2026
- -$108M+21.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +138.8% | -23.2% | -162.0 pp |
| 1 year | +105.2% | -62.1% | -167.3 pp |
| 3-year CAGR | +44.8% | -34.6% | -79.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (140.95M) USD
- Year-over-year change
- -105.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (140.95M) | -105.2% |
| FY2024 | 2024-12-31 | (68.69M) | +10.9% |
| FY2023 | 2023-12-31 | (77.09M) | -66.0% |
| FY2022 | 2022-12-31 | (46.45M) | -19.9% |
| FY2021 | 2021-12-31 | (38.74M) | — |
Net Income vs competitors
How GUTS compares with its peers on the latest reported figures
- GUTS's LTM Mar 2026 net income of $108M is the 2nd largest of the 7 companies compared; the peer median is $78.55M.
- Its year-over-year change of +21.2% is the 3rd highest of 7, against a peer median of -10.6%.
- Over three fiscal years its annual growth of +44.8% compares with a peer median of +3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $108M | +21.2% | +44.8% | — | |
| LTM Mar 2026 | $88.87M | -31.7% | -6.3% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M | +21.4% | +12.6% | — |
| LTM Mar 2026 | $70.03M | +10.4% | +17.8% | 36859.5% | |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $43.6M | +98.3% | -25.7% | 96.7% | |
| Peer median (excluding GUTS) | $78.55M | -10.6% | +3.2% | 154.2% | |
Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Depreciation & Amortization | 676K | 452K | 286K | 677K | 1.13M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.09M | 3.14M | 4.3M | 14.43M | 6.68M |
| Change in Working Capital | 1.71M | (1.24M) | 989K | 9.59M | (395K) |
| Accounts Receivables | 0 | 0 | (22K) | 22K | 0 |
| Inventory | 0 | 0 | (73K) | 0 | 73K |
| Accounts Payables | 666K | 0 | (427K) | 2.69M | (1.67M) |
| Other Working Capital | 1.05M | (1.24M) | 1.51M | 6.88M | 1.2M |
| Other Non-Cash Items | 795K | (2.14M) | 28.7M | (21.52M) | 43.21M |
| Operating Cash Flow | (33.46M) | (46.24M) | (42.82M) | (65.52M) | (90.33M) |
| Capital Expenditures | (51K) | (56K) | (359K) | (1.77M) | (557K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (51K) | (56K) | (359K) | (1.77M) | (557K) |
| Debt Repayment | (7K) | 4.03M | 28.35M | (187K) | (457K) |
| Common Stock Issued | 0 | 321K | 0 | 103.7M | 105.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 40K | 0 | (911K) | (2.28M) | 0 |
| Financing Cash Flow | 99.88M | 4.35M | 27.44M | 101.23M | 104.96M |
| Effect of Forex Changes | 0 | (4.26M) | 0 | 0 | 0 |
| Net Change in Cash | 66.37M | (46.2M) | (15.75M) | 33.94M | 14.08M |
| Free Cash Flow | (33.51M) | (46.3M) | (43.18M) | (67.29M) | (90.89M) |
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
Intrinsic Alpha fair value
Locked
Current Price
$4.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.